In fact the administration of osthole (daily dose of 30 mg/kg body weight by intraperitoneal injection) improved an accelerated, early stage, focal segmental glomerulosclerosis mouse model by activating Nrf2 and subsequently inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells- (NF-κB)-mediated cyclooxygenase 2- (Cox-2) expression and apoptosis [137]. Here, PTGS2 is linked to focal segmental glomerulosclerosis.